Showing 1 - 10 of 16
Developing nations are challenged to strike a balance between their patent obligations as members of the World Trade Organisation (WTO) and their drug pricing strategies. The Brazilian approach to pharmaceutical price negotiations has been strikingly effective. Describing the context of the...
Persistent link: https://www.econbiz.de/10005202494
Persistent link: https://www.econbiz.de/10007426674
Este informe presenta una selección de estudios sobre transparencia y corrupción que abarcan desde la relación de la corrupción con los fenómenos socioeconómicos hasta los vínculos entre implementación de políticas y cambios. El punto de partida es el análisis empírico de la...
Persistent link: https://www.econbiz.de/10010772413
Este informe presenta una selección de estudios sobre transparencia y corrupción que abarcan desde la relación de la corrupción con los fenómenos socioeconómicos hasta los vínculos entre implementación de políticas y cambios. El punto de partida es el análisis empírico de la...
Persistent link: https://www.econbiz.de/10010943478
This study presents a diagnostic framework and methodology to evaluate a pharmaceutical system s vulnerability to corruption and to determine which corrupt practices can have a major impact on the system s ultimate efficiency. We thus provide: (a) a systematic and quantifiable assessment of the...
Persistent link: https://www.econbiz.de/10012572248
Persistent link: https://www.econbiz.de/10011033925
Although pharmaceutical counterfeiting incidents can be traced back thousands of years, it has been downplayed and even dismissed by pharmaceutical manufacturers in the past. That has changed. Pharmaceutical firms are newly dedicated to eradicate counterfeits globally and spending more money on...
Persistent link: https://www.econbiz.de/10005443224
Persistent link: https://www.econbiz.de/10005412117
The debate over access to medicines has principally centered on pharmaceutical patents and prohibitively high drug prices. Although a less recognized problem, counterfeit pharmaceuticals are certainly a more insidious barrier to access. Pharmaceutical counterfeiting is an invisible threat, not...
Persistent link: https://www.econbiz.de/10005694750
The resource-based view of the firm suggests that direct control over unique assets can form the basis of sustained competitive advantage. In contrast, the papers presented in this Special Issue examine the payoffs to cross-boundary resource management. These papers demonstrate the potency of...
Persistent link: https://www.econbiz.de/10005200281